Business Wire

FLEXTRADE-SYSTEMS

Share
FlexTrade Breaks New Ground with Artificial Intelligence Functionality Available in FlexTRADER EMS

FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, has announced the launch of artificial intelligence-driven (AI) functionality within its flagship multi-asset solution, FlexTRADER EMS. The new interface layer is designed to revolutionize how trading teams interact with their data and trading technology solutions.

Over the past year, OpenAI driven-solutions such as ChatGPT and its latest version, GPT-4, which apply natural language processing to large language model (LLM) systems, have been in the spotlight, with firms racing to understand their uses for the trading space. However, the new offering from FlexTrade is one of the first practical examples of the technology being used directly within an OEMS solution.

The groundbreaking innovation, which has the working name of FlexA, is a voice-activated application developed by FlexTrade's in-house data science team as part of its ongoing R&D function and commitment to delivering innovation to its customer base. The solution provides an AI layer across FlexTRADER EMS to simplify the interaction between the trader and their trading technology platform and easily and intuitively work with vast swathes of information outside the more traditional 2D grid visualization and input devices currently used.

With the new solution, traders using FlexTRADER EMS, with FlexA enabled, can apply natural language to interrogate and control the solution via voice commands or a text-based chat interface in several ways. For instance, clients can ask verbal or written questions to quickly and easily achieve a deep situational awareness of orders within their blotter using a combination of specific criteria or characteristics such as "What is the value of my Swiss orders over 10% ADV?". Additionally, traders can request ad-hoc reports on historical trading with specific visualization formats, including tables and charts, to assist with pre-trade decision-making. For example: "Show me a chart of my traded venues for US orders in Feb." Furthermore, traders can send actions to be automated to help speed up workflow. For instance, "create a ticket for my US orders less than 500k using the VWAP AlgoWheel" or "merge AAPL."

Vijay Kedia, CEO, FlexTrade Systems Inc., stated: "The introduction of OpenAI and ChatGPT is a revolutionary moment in consumer technology, and the speed at which we've incorporated it across FlexTRADER EMS is a milestone achievement. It enables traders to use natural language to rapidly interact, interrogate and understand data in the manner which makes the most sense to them. The outcome is that it erodes the barriers created by traditional input devices such as keyboard and mouse, enabling trading teams to work quickly to understand and optimize their pre-trade decisions, which is paramount in a constantly changing environment."

Vikas Kedia, Managing Director of Strategic Initiatives & Emerging Solutions at FlexTrade, commented: "FlexTrade's R&D and innovation teams continuously and proactively evaluate the latest technologies, as they become available, to understand the practical applications to buy-and-sell-side trading desks. From machine learning and our sophisticated real-time market impact analytics offering to, most recently, AI, we are working with our client base and business users to refine and explore further applications across global trading desks. It's an approach that ensures our clients stay at the forefront of cutting-edge developments in trading technology."

About FlexTrade Systems:

FlexTrade Systems is a global leader in high-performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world's first broker-neutral execution management trading system. It allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005117/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye